title: Runx2 association with progression of prostate cancer in patients: mechanisms mediating bone osteolysis and osteoblastic metastatic lesions.
abstract: Runx2, a bone-specific transcriptional regulator, is abnormally expressed in highly metastatic prostate cancer cells. Here, we identified the functional activities of Runx2 in facilitating tumor growth and osteolysis. Our studies show that negligible Runx2 is found in normal prostate epithelial and non-metastatic LNCaP prostate cancer cells. In the intra-tibial metastasis model, high Runx2 levels are associated with development of large tumors, increased expression of metastasis-related genes (MMP9, MMP13, VEGF, Osteopontin) and secreted bone-resorbing factors (PTHrP, IL8) promoting osteolytic disease. Runx2 siRNA treatment of PC3 cells decreased cell migration and invasion through Matrigel in vitro, and in vivo shRunx2 expression in PC3 cells blocked their ability to survive in the bone microenvironment. Mechanisms of Runx2 function were identified in co-culture studies showing that PC3 cells promote osteoclastogenesis and inhibit osteoblast activity. The clinical significance of these findings is supported by human tissue microarray studies of prostate tumors at stages of cancer progression, in which Runx2 is expressed in both adenocarcinomas and metastatic tumors. Together these findings indicate that Runx2 is a key regulator of events associated with prostate cancer metastatic bone disease.
authors.affiliation: The Cancer Center Prostate Cancer Discovery and Development Program, University of Massachusetts Medical School, Worcester, MA, USA.
authors.forename: J
authors.initials: J
authors.lastname: Akech
authors.forename: J J
authors.initials: JJ
authors.lastname: Wixted
authors.forename: K
authors.initials: K
authors.lastname: Bedard
authors.forename: M
authors.initials: M
authors.lastname: van der Deen
authors.forename: S
authors.initials: S
authors.lastname: Hussain
authors.forename: T A
authors.initials: TA
authors.lastname: Guise
authors.forename: A J
authors.initials: AJ
authors.lastname: van Wijnen
authors.forename: J L
authors.initials: JL
authors.lastname: Stein
authors.forename: L R
authors.initials: LR
authors.lastname: Languino
authors.forename: D C
authors.initials: DC
authors.lastname: Altieri
authors.forename: J
authors.initials: J
authors.lastname: Pratap
authors.forename: E
authors.initials: E
authors.lastname: Keller
authors.forename: G S
authors.initials: GS
authors.lastname: Stein
authors.forename: J B
authors.initials: JB
authors.lastname: Lian
mesh_terms: D000818:Animals; D001859:Bone Neoplasms / Q000235:genetics / Q000473:pathology* / Q000556:secondary*; D045744:Cell Line, Tumor; D002465:Cell Movement; D049109:Cell Proliferation; D050659:Core Binding Factor Alpha 1 Subunit / Q000172:deficiency / Q000235:genetics / Q000378:metabolism*; D018450:Disease Progression; D015972:Gene Expression Regulation, Neoplastic; D055785:Gene Knockdown Techniques; D006801:Humans; D008297:Male; D051379:Mice; D016513:Mice, SCID; D010006:Osteoblasts / Q000378:metabolism / Q000473:pathology*; D010010:Osteoclasts / Q000378:metabolism / Q000473:pathology; D010014:Osteolysis / Q000378:metabolism / Q000473:pathology*; D011471:Prostatic Neoplasms / Q000188:drug therapy / Q000235:genetics / Q000473:pathology*; D013977:Tibia / Q000378:metabolism / Q000473:pathology; D046888:Tissue Array Analysis; D015533:Transcriptional Activation
chemical_list: D050659:Core Binding Factor Alpha 1 Subunit